Perifosine (KRX-0401)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 16:51, 14 November 2014 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== AKT and PI3K inhibitor ==Preliminary data== ===Hodgkin lymphoma=== # Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S,...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

AKT and PI3K inhibitor

Preliminary data

Hodgkin lymphoma

  1. Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clin Cancer Res. 2014 Sep 19. [Epub ahead of print] link to original article PubMed

History of changes in FDA indication

  • 9/3/2009: Received FDA orphan drug designation for treatment of multiple myeloma.
  • 7/9/2010: Received FDA orphan drug designation for treatment of neuroblastoma.
Retrieved from "https://hemonc.org/w/index.php?title=Perifosine_(KRX-0401)&oldid=5687"